Uroselective alpha-blockade for benign prostatic hyperplasia: clinically significant or marketing savvy?
Kaplan
S A
SA
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D011470:Prostatic Hyperplasia / Q000188:drug therapy*; D014572:Urology
D000317:Adrenergic alpha-Antagonists